Sonoma Biotherapeutics Raises $265 Million In An Oversubscribed Series B Financing To Translate The Promise Of Cell Therapy Into Curative Medicines For Autoimmune And Other Inflammatory Diseases
Sonoma Biotherapeutics Raises $265 Million In An Oversubscribed Series B Financing To Translate The Promise Of Cell Therapy Into Curative Medicines For Autoimmune And Other Inflammatory Diseases
08/04/21, 11:05 AM
Location
san franciscoMoney raised
$265 million
Industry
agriculture and farming
biotechnology
science and engineering
health care
Round Type
series b
Sonoma Biotherapeutics, an immune tolerance company focused on the development of regulatory T cell (Treg) therapies, has announced an oversubscribed $265 million Series B financing. Proceeds from the financing will be used to advance Sonoma Bio’s Treg cell therapy platform and a novel Teff conditioning biologic into the clinic to treat multiple, severe autoimmune and inflammatory diseases and to further invest in and scale up manufacturing operations in order to support supply for initial clinical studies.
Company Info
Location
san francisco, california, united states
Additional Info
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.